In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.
|Articles|May 5, 2003
New fluoroquinolone has dual activity against resistant bugs
Physicians will soon have a fourth-generation fluoroquinolone with dual activity against bacteria to treat persons with community-acquired respiratory infections. The FDA recently approved gemifloxacin (Factive, GeneSoft Pharmaceuticals) for the treatment of acute bacterial exacerbation of chronic bronchitis (AECB) caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis and community-acquired pneumonia (CAP) of mild-to-moderate severity caused by S. pneumoniae (including penicillin-resistant strains), H. influenzae, M. catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae. Gemifloxacin will be available in pharmacies by the end of the year.
Advertisement
Advertisement
Related to this article
Pharmacist-backed picks help families manage fever and pain, seasonal allergies, and cough and congestion as kids head back to the classroom.
Sara Hover, RPh, FAARM, explains how these products are putting pharmacists at the center of safety and evidence evaluations one patient at a time.
Independent pharmacies adapt to specialty drugs, biosimilars, cold-chain, and REMS demands.
During American Pharmacists Month, pharmacy teams reflect on their roles and explore ways to enhance patient care.
Lara Zakaria, PharmD, MS, CNS, FMCP, discusses her perspectives regarding the emergence of wearable technology among community pharmacy patients.
Diabetes medication experts focus on practical access and pharmacist counseling considerations for adults on obesity medication.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Improve Access, Safe Use of Obesity Medications
2
Is Your Independent Pharmacy Ready for New Therapies and Innovations?
3
FDA Approves New Drug for HSV Lesions in Adults
4
PrEP Deserts: Why HIV Prevention Still Misses Those at Risk
5